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There is conﬂicting evidence on the contribution of the MCP-1 −2518 A>G (rs 1024611) polymorphism to SLE incidence and
clinical manifestations. We examined the prevalence of the MCP-1 −2518 A>G polymorphism in SLE patients (n = 199) and
controls (n = 250) in Poland. We did not observe a signiﬁcant diﬀerence in the distribution of MCP-1 −2518 A>G polymorphic
variants in patients with SLE and healthy individuals. However, we found an association between the GG versus AG and AA
genotypesaswell astheAGandGGversusAAgenotypes withrenalmanifestationsofSLEOR = 3.614(1.123–11.631,P = 0.0345)
and OR = 2.297 (1.301–4.057, P = 0.0046), respectively. We also observed that the MCP-1 AG and GG -genotypes contribute to
the occurrence of thrombocytopenia in SLE patients OR = 2.618 (1.280–5.352, P = 0.0089). Our observations indicate that either
MCP-1 −2518 G variant can be associated with some clinical ﬁndings in patients with SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a chronic and pro-
gressivemultisystemautoimmuneconnectivetissuedisorder,
which is characterized by immune-mediated host tissue
destruction [1]. Occupational exposure, chemicals, drugs,
f o o d ,a sw e l la sv i r a la n db a c t e r i a li n f e c t i o u sa g e n t sc a n
contribute signiﬁcantly to changes in the immune system
[2, 3].
Immune cells from patients with SLE exhibit various
defects including skewed cytokine production, a decrease in
cytotoxic T cell function, and an increase in the humoral
response [4–7]. The defective function of CD4+ T cells asso-
ciated with abnormal stimulation of B cells causes abundant
autoantibody production [4, 6]. These autoantibodies form
immune complexes with antigens on the patient’s own cells
and are accumulated in the skin, synovium, lungs, renal
glomeruli, and other organs and tissues. This results in the
clinical presentation of SLE [1, 8].
The pathogenesis of SLE remains unclear, though there
is much evidence demonstrating the involvement of genetic
factors in the incidence of this autoimmune disease [9–13].
The genetic background contributing to SLE development
includes,inparticular,genesencodingdisparateproteinsthat
c o n t r o li m m u n es y s t e mp a t h w a y s[ 9, 10, 13].
The monocyte chemoattractant protein 1 (MCP-1), cur-
rently also designated CCL2, belongs to the family of chemo-
tactic cytokines. MCP-1 functions as a potent agonist for
monocytes, memory T cells, and basophils [14]. Evidence in
animalandhumanstudiessuggestsasigniﬁcantroleofMCP-
1 in the progression of glomerular and tubulointerstitial
injuries and glomerulonephriti in patients with SLE [15–19].
It has been demonstrated that the MCP-1 –2518 A>G( r s
1024611) transition in the promoter region may modulate2 Journal of Biomedicine and Biotechnology
the levels of MCP-1 expression [20, 21]. The MCP-1 –2518
G allele, compared to the –2518 A allele, is linked with
increased production of both MCP-1 transcript and protein
[20, 21]. Involvement of the MCP-1 –2518 A>Gp r o m o t e r
polymorphism in SLE development and its contribution to
some clinical manifestations of SLE remains controversial
[22–28]. We analysed the distribution of functional MCP-1
–2518 A>G polymorphic variants in SLE patients (n = 199)
and controls (n = 250).
2. Patientsand Methods
2.1.PatientsandControls. Onehundredninetynine(women
only) patients fulﬁlling the American College of Rheuma-
tology Classiﬁcation criteria for SLE [29, 30] were chosen
for investigation at Institute of Rheumatology in Warsaw,
Poland(Table 1).Twohundredandﬁftyhealthywomenwere
included as controls. The protocol of the study was approved
by the Local Ethical Committee of Pozna´ n University of
Medical Sciences. Written agreement was obtained from
patients and controls. All participating subjects were of
Polish and Caucasian origin. The mean age of SLE patients at
diagnosis was 36 ± 12 years, and of controls, 35 ± 11 years.
2.2. Genotyping. DNA was isolated from peripheral white
blood cells employing a standard salting out procedure.
The presence of the MCP-1 –2518 A>G (rs 1024611)
polymorphic variant was identiﬁed by polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP). PCR was carried out using primer pair 5 -CTTTCC-
CTTGTGTGTCCCC-3  and 5 -TTACTCCTTTTCTCC-
CCAACC-3 . The PCR-ampliﬁed fragments of MCP-1 that
were940bpinlengthwereisolatedandsubjectedtodigestion
withendonucleasePvuII(CAG/CTG)(NewEnglandBiolabs,
Ipswich, USA). The MCP-1 –2518 G allele was cleaved into
650bp and 290bp fragments; whereas the MCP-1 –2518 A
allele remained uncut. DNA fragments were separated by
electrophoresison2%agarosegelandvisualizedbyethidium
bromidestaining.PresenceoftheMCP-1polymorphism was
additionally conﬁrmed by commercial sequencing analysis.
2.3. Statistical Analysis. T h ep r e v a l e n c eo fg e n o t y p e si n
patients and controls was examined for deviation from
Hardy-Weinberg equilibrium. Uncorrected Chi2 test was
employed to examine diﬀerences in genotypic and allelic dis-
tribution between patients and controls. Moreover, the Odds
Ratio (OR) and 95% Conﬁdence Intervals (95% CI) were
calculated. A P-value < 0.05 was considered statistically sig-
niﬁcant. Associations between clinical manifestations, pro-
duction of autoantibodies, and polymorphism distribution
in patients with SLE were determined by Fisher exact test.
The Mann-Whitney test for nonparametric data was used
to determine the statistical diﬀerence in SLE disease activity
index (SLEDAI) [31] between MCP-1 GG, AG, and AA
genotypegroups.Poweranalysiswasperformedusinguncor-
rected Chi2 test, which is available at an online internet ser-
vice: http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/
PowerSampleSize.
3. Results
3.1. Distribution of MCP-1 –2518 A>G Genotypes and Alleles
in SLE Patients and Healthy Individuals. Genotype analysis
of the MCP-1 –2518 A>G polymorphism did not reveal a
signiﬁcant deviation form Hardy-Weinberg equilibrium in
any group. We did not observe a signiﬁcant diﬀerence in the
prevalence of the MCP-1 –2518 A>Gp o l y m o r p h i cv a r i a n t
in patients with SLE and healthy individuals (Table 2). OR
for SLE patients with the GG genotype was 0.8629 (95% CI
= 0.4428–1.682, P = 0.6647), and OR of the GG and AG
genotypes was 0.9320 (95% CI = 0.6421–1.353, P = 0.7111)
(Table 2). The power of this study amounted to 7.0% for
the GG genotype and 6.6% for the GG and GA genotypes.
We also did not observe a diﬀerence in the distribution of
alleles between patients and controls. OR for the MCP-1 –
2518 G allele frequency was 0.9314 (95% CI = 0.6963–1.246,
P = 0.6320).
3.2. Association of MCP-1 –2518 A>G Genotypes with Clinical
Symptoms of SLE. Since the previous studies indicated the
contribution of either MCP-1 –2518 GG or AG genotypes
to some clinical SLE manifestations [22, 23, 28], we assessed
the association of these genotypes to clinical ﬁndings in
our investigated group. We observed the association between
the GG versus AG and AA genotypes and AG and GG
versus AA genotypes with renal manifestations of SLE OR
= 3.614 (1.123–11.631, P = 0.0345) and OR = 2.297 (1.301–
4.057, P = 0.0046), respectively (Table 1). However, these P-
valuesdidnotremainstatisticallysigniﬁcantafterBonferroni
correction (Pcorr = 0.621; Pcorr = 0.0828, resp.). We observed
an association between the GG versus AA genotypes with
renal manifestations OR = 4.923 (1.483–16.343, P = 0.0067)
(Pcorr = 0.1206) (Table 1). There was also an association
of the MCP-1 (AG and GG versus AA) genotypes with
occurrence of thrombocytopenia OR = 2.618 (1.280–5.352,
P = 0.0089) (Pcorr = 0.1602) in SLE patients (Table 1).
We did not ﬁnd a signiﬁcant association between the GG
genotype or G allele with the presence of anti-dsDNA, anti-
Smith,anti-snRNP,anti-Ro,anti-Scl-70,orantiphospholipid
antibodies. There were also no signiﬁcant diﬀerences in
SLEDAI at diagnosis between MCP-1 GG, AG, and AA
genotype groups.
4. Discussion
Completion of the human genome project revealed the
existence of approximately ten million single nucleotide
polymorphisms (SNPs). However, the role of SNPs in states
of either health or sickness remains under investigation [32].
To date, the MCP-1 –2518 A>Gp o l y m o r p h i s mh a s
been associated with coronary artery disease, nonfamilial
idiopathic dilated cardiomyopathy, carotid atherosclerosis
in patients with type 2 diabetes, myocardial infarction,
ischemic heart disease, and hypertension [33–38]. Moreover,
the MCP-1 –2518 G variant may also contribute to ocular
Behc ¸et’s disease, adult and juvenile type of rheumatoid
arthritis, systemic sclerosis, and psoriasis [39–43].Journal of Biomedicine and Biotechnology 3
Table 1: Association of the MCP-1 –2518 A>G polymorphism with clinical manifestation in patients with SLE.
Characteristic Genotypes distribution
A/A (103)(a) A/G (80)(a) G/G (16)(a) Odds ratio (95% CI), P (e)
Malar rash 46 39 6
Discoid rash 32 23 5
Photosensitivity 47 38 7
Oral ulcers 41 32 6
Arthritis 59 42 8
Serositis 18 13 3
Renal 39 44 12
3.614 (1.123–11.631, P = 0.0345)(b)
2.297 (1.301–4.057, P = 0.0046)(c)
4.923 (1.483–16.343, P = 0.0067)(d)
Neurologic symptoms 19 16 4
Hematologic symptoms 28 23 6
Thrombocytopenia 14 23 5 2.618 (1.280–5.352, P = 0.0089)(c)
Leukopenia 21 16 3
Immunologic symptoms 51 43 7
ANA 103 80 16
(a)represents the absolute number of positive patients for A/A, A/G, A/G genotypes, respectively.
Comparison genotype (b)(G/G versus A/A and A/G); (c)(G/G and A/G versus A/A); (d)(G/G versus A/A), between patients with and patients without a
manifestation was performed by (e)Fisher exact test.
Table 2: Association of the MCP-1 –2518 A>G polymorphisms in SLE patients and controls.
MCP-1 –2518 A>G (rs1024611) SLE n = 199 (%) Controls n = 250 (%) OR 95%CI (d)P-value
Genotype frequency
A/A 103 (51.8) 125 (50.0)
A/G 80 (40.2) 102 (40.8)
G/G 16 (8.0) 23 (9.2) 0.8629(a) 0.4428–1.682 0.6647
A/G+ G/G 96 (48.2) 125 (50.0) 0.9320(b) 0.6421–1.353 0.7111
Allele frequency
A 286 (71.9) 352 (70.4)
G 112 (28.1) 148 (29.6) 0.9314(c) 0.6963–1.246 0.6320
The Odds ratio was calculated for patients (a)(G/G genotype versus A/G and A/A genotypes); (b)(G/G and A/G genotype versus A/A genotype).
We also determined the OR for the patients’ minor allele (c)(G versus A allele); (d)uncorrected Chi2.
Reports on the contribution of the MCP-1 –2518 A>G
polymorphism to SLE incidence and clinical manifestations
have been inonsistent [22–28, 44, 45]. We did not observe
diﬀerences in the distribution of the MCP-1 –2518 A>G
polymorphic variant between patients with SLE and healthy
individuals; however this may be due to the low power of our
investigation.
There have been no reports of a contribution of either
the MCP-1 AG or GG genotype to SLE incidence in African
American,Spanish,Korean,andMexicancohorts[23–26,44,
45]. By contrast, Tucci et al. showed a signiﬁcant association
of the MCP-1 AG and GG genotypes to SLE incidence in
patients from North America [22]. Moreover, Brown et al.
found that Caucasians bearing the MCP-1 –2518 G allele
exhibited a signiﬁcantly increased risk of developing SLE
[26].
These conﬂicting reports on the eﬀect of the MCP-
1 –2518 A>G polymorphism to the incidence of SLE in
various populations may be due to diﬀerences in the racial
heterogeneity of the examined groups. This disparity may
alsohaveresultedfromeachpopulation’sexposuretodistinct
environmental factors, which may act in synergy with the
MCP-1 –2518 A>G polymorphism to change the risk of SLE
incidence among the studied populations [3].
We observed that the MCP-1 G/G and A/G genotypes
contribute to renal manifestations of the disease. A cor-
relation between the MCP-1 –2518 G allele and nephritis
was also observed in a North American SLE cohort [22].
Furthermore, the MCP-1 –2518 G allele was associated with
cutaneous vasculitis in a Spanish SLE group [23], arthritis
in Chinese adults with SLE [28] and the presence of anti-
dsDNAandantiphospholipidantibodiesinMexicanpatients
with SLE [45].
The MCP-1 –2518 A>G polymorphism is located at
a relatively proximal position to the major transcriptional
start site of the MCP-1 gene. Rovin et al. cloned the distal
regulatory region of a luciferase reporter gene, including
the MCP-1 –2518 A>G polymorphic variant upstream of4 Journal of Biomedicine and Biotechnology
the reporter gene [20]. They indicated that peripheral
blood mononuclear cells with either the MCP-1 AG or GG
genotypedemonstratedincreasedinterleukin1beta-induced
MCP-1 transcription compared to cells with genotype AA
[20]. Moreover, Fenoglio et al. also showed that Alzheimer’s
disease patients bearing at least one MCP-1-2518 G allele
exhibited a signiﬁcant increase of MCP-1 levels in blood
plasma [21].
It has been reported that diﬀerent renal cells, including
glomerular endothelial, mesangial, and tubular epithelial
cells,areabletobiosynthesizeMCP-1inresponsetoimmune
complexesorsomeproinﬂammatorycytokines[46–48].This
MCP-1 production by renal cells can be enhanced by the
MCP-1 –2518 G variant leading to the renal manifestations
of SLE observed in both our investigation and other studies
[22].
We also found that the MCP-1 GG and AG genotypes
are associated with thrombocytopenia. An increase in serum
levels of MCP-1 has previously been linked to elevated solu-
ble CD40L in patients with autoimmune thrombocytopenic
purpura [49].
The platelets of SLE patients are perpetually activated,
andthesepatientsexhibitanincreaseofsolubleCD40Llevels
in the blood plasma [50, 51]. The interaction of CD40L from
activated platelets with CD40 on endothelial cells induces
an inﬂammatory reaction in the endothelium leading to the
secretion of chemokines, including MCP-1 [52]. This may
produce signals for the recruitment and extravasations of
macrophages, which are able to interact with anti-platelet
antibodies complexed with the platelets, which may lead to
platelet destruction [49].
Our genetic investigation suggests that the MCP-1 –2518
G variant can contribute to some clinical ﬁndings in patients
with SLE. However, to more precisely evaluate the eﬀect of
the MCP-1 –2518 G variant on SLE manifestations, further
examination of this variant’s distribution in other sample
populations is required.
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